التفاصيل البيبلوغرافية
| العنوان: |
Safety and efficacy of 2‐weekly cabazitaxel in metastatic castration‐resistant prostate cancer. |
| المؤلفون: |
Clément‐Zhao, Alice, Auvray, Marie, Aboudagga, Hail, Blanc‐Durand, Félix, Angelergues, Antoine, Vano, Yann Alexandre, Mercier, Florence, El Awadly, Nader, Verret, Benjamin, Thibault, Constance, Oudard, Stéphane |
| المصدر: |
BJU International; Feb2018, Vol. 121 Issue 2, p203-208, 6p |
| مصطلحات موضوعية: |
CABAZITAXEL, CASTRATION-resistant prostate cancer, DRUG efficacy, DRUG toxicity, MEDICATION safety, CANCER treatment |
| مستخلص: |
Objectives: To evaluate the safety and efficacy of a 2‐weekly cabazitaxel schedule in patients with metastatic castration‐resistant prostate cancer (mCRPC). Materials and methods: During the period October 2013 to February 2016, 43 patients with mCRPC were treated with cabazitaxel (16 mg/m2, on days 1 and 15 of a 4‐week cycle) together with prophylactic granulocyte colony‐stimulating factor (G‐CSF). The safety profile and efficacy (prostate‐specific antigen [PSA] response; biological, clinical or radiological progression‐free survival [PFS] and overall survival [OS]) of the treatment were analysed. Results: All patients had received prior docetaxel and 79.1% abiraterone acetate. At inclusion, 46.5% were aged >70 years and 27.9% had an Eastern Cooperative Oncology Group performance status ≥2. Six patients stopped treatment because of toxicity. Grade ≥3 toxicities were: asthenia (16.3%); neutropenia (11.6%); thrombocytopenia (9.3%); diarrhoea (7%), anaemia (4.7%), febrile neutropenia (4.7%) and haematuria (2.3%). In all, 52.4% achieved a ≥30% PSA response and 40.5% had a ≥50% PSA response. The median OS was 15.2 months. Conclusion: This prospective pilot study suggests that cabazitaxel 16 mg/m² given 2‐weekly has a manageable toxicity profile in docetaxel‐ and abiraterone acetate‐pretreated patients with mCRPC. A prospective phase III trial comparing this regimen with the standard cabazitaxel regimen is planned to confirm these results. [ABSTRACT FROM AUTHOR] |
|
Copyright of BJU International is the property of Wiley-Blackwell and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| قاعدة البيانات: |
Complementary Index |
Full Text Finder